Data Year:

For its 2024 fiscal year, BICYCLE THERAPEUTICS PLC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2024
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Kevin Lee Ph.D., MBA
Chief Executive Officer
Total Compensation $4,857,218 View details Pay Rank By Title In Biotechnology industry #273 View more
Alistair Milnes
Chief Operating Officer
Total Compensation $2,591,573 View details Pay Rank By Title In Biotechnology industry #69 View more
Santiago Arroyo M.D., Ph.D.
Chief Development Officer
Total Compensation $2,607,884 View details Pay Rank By Title In Biotechnology industry #128 View more
Alethia Young
Chief Financial Officer
Total Compensation $1,470,372 View details Pay Rank By Title In Biotechnology industry #299 View more
Michael Hannay D.Sc.
Chief Product and Supply Chain Officer
Total Compensation $2,365,453 View details Pay Rank By Title In Biotechnology industry #151 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at BICYCLE THERAPEUTICS PLC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. BICYCLE THERAPEUTICS PLC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. BICYCLE THERAPEUTICS PLC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Kevin Lee Ph.D., MBA
Chief Executive Officer
Total Cash $1,412,777 Equity $3,359,659 Other $84,782 $4,857,218
Alistair Milnes
Chief Operating Officer
Total Cash $848,791 Equity $1,682,523 Other $60,259 $2,591,573
Santiago Arroyo M.D., Ph.D.
Chief Development Officer
Total Cash $967,500 Equity $1,626,584 Other $13,800 $2,607,884
Alethia Young
Chief Financial Officer
Total Cash $879,300 Equity $521,605 Other $69,467 $1,470,372
Michael Hannay D.Sc.
Chief Product and Supply Chain Officer
Total Cash $660,399 Equity $1,667,070 Other $37,984 $2,365,453
For its 2024 fiscal year, BICYCLE THERAPEUTICS PLC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Kevin Lee Ph.D., MBA CEO Pay $4,857,218 Median Employee Pay $203,298 CEO Pay Ratio 24:1
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.